Triple-Negative Breast Cancer: Expert Perspectives On Recent Advances

home / peer-exchange / triple-negative-breast-cancer-expert-perspectives-on-recent-advances

EP. 1: Standard of Care for Early-Stage TNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 2: Role of pCR in Early Stage TNBC Management

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 3: Key Trials in ICI-Based Therapy for Early Stage TNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 4: Early Stage TNBC: Phase 3 IMpassion031 Study

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 5: Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 6: ICI-Based Therapy in TNBC: Immune-Related Adverse Events

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 7: Emerging Data on Biomarkers in ES TNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 8: Current Trials for Treatment of Early Stage TNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 9: Standard of Care for Metastatic TNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 10: KEYNOTE-355 Trial in mTNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 11: Testing for PD-L1 Expression in mTNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 12: Standard of Care for BRCA+ mTNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 13: Sequencing Therapies for mTNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 14: Phase 3 ASCENT Trial in mTNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 15: Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

EP. 16: Future Directions for Treatment of TNBC

By Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute

October 23rd 2020

Latest Conference Coverage

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512